Not only is gonorrhoea becoming increasingly common, but rising antibiotic resistance is making the once easily curable infection increasingly difficult to treat, reports Katharine Lang Drug resistant ...

Point-of-care testing for common sexually transmitted infections may reduce overuse of antibiotics and improve emergency ...

Researchers with the Hawaii Department of Health identified a cluster of Neisseria gonorrhoeae infections that displayed a decreased susceptibility to the double-antibiotic combination used to ...

Postexposure prophylaxis with doxycycline (DoxyPEP) was associated with a substantial decline in the incidence ofsexually transmitted infections (STIs) including Chlamydia trachomatis and Neisseria ...

LAUSANNE, Switzerland & BOSTON--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure ...

LAUSANNE, Switzerland & BOSTON--(BUSINESS WIRE)--Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company, is proud to announce the extension of funding from the Combating ...

FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea ...

Gonorrhoea, a common sexually transmitted infection (STI) that often doesn't come with symptoms, has become harder to treat as bacteria develop resistance to existing antibiotics. If left untreated, ...

Gonorrhoea is resistant to nearly all antibiotics, but one commonly used for urinary tract infections (UTIs) may be able to treat drug-resistant cases. The sexually transmitted infection (STI) is ...

With Debio 1453, Debiopharm aims to provide a potentially valuable addition to the current antibiotic armamentarium, as a new treatment for N. gonorrhoeae infections, especially strains showing ...